0.
[022引巧]Catalona, W. J.，Partin, A. W.，Slawin, Κ· Μ·，Brawer, Μ· Κ.等，Use of the percentage of free prost过te-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. Jama 1998,279, 1542-1547.
[0229][6]Bjork, T.，Lilja, H.，Christensson, A.，The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer. BJU Int 1999, 84, 1021-1027.
[0230] 口]Gann, P.比，Ma, J.，Catalona, W. J.，Stampfer, M. J.，Strategies combining total and percent free prostate specific antigen for detecting prostate canceria prospective evaluation. J Urol 2002,167,2427-2434.
[0231] 巧]Cancer Diagnostic Testing World Markets, TriMark Publications, LiX 2008.
[023引[9] Vickers, A. J.，Cronin, A. M.，Aus, G.，PiLhl, C. G.等，A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Med 2008, 6, 19.
[0233][10] Vickers, A. J.，Gupta, A.，Savage, C. J.，Pettersson, K.等，A panel of kallikrein marker predicts prostate cancer in a large，population-based cohort followed for 15years without screening. Cancer Epidemiol Biomarkers Prev 2011,20, 255-261.
[0234] [ll]Jansen, F. H.，van Schaik,民.H.，Kurstjens, J.，Horninger, W. 等，Prostate-specific antigen(PSA)isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010, 57,921-927.
[0235][12] Stephan, C.，Jung, K.，Lein, M.，Sinha, P.等，Molecular forms of prostate-specific antigen and human kallikrein 2as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol Biomarkers Prev 2000,9, 1133-1147.
[0236][13]Becker, C.，Piiro打e打，T.，Pettersso打，K.，Bjork, T.等，Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2(服2)in serum. J Urol 2000,163,311-316.
[0237] [ 14] Pi ironen, T.，Haese, A.，Hu land, H.，St euber, T.等，Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. Clin Chem 2006, 52, 838-844.
[0238][15] Thompson, T. C.，Truong, L. D.，Timme, T. L.，Kadmon, D.等，Transforming growth factor beta las a biomarker for prostate cancer. J Cell Biochem Suppl 1992, 16H，54-61.
[0239] [16] Shariat, S. F.，Kattan, M. W.，Traxel, E.，An虹ews, B.等，Association of pre-and postoperative plasma levels of transforming growth factor beta(1)and interleukin 6and its soluble receptor with prostate cancer progression. Clin Cancer Res 2004, 10, 1992-1999.
[0240][17]Hobisch, A.，Eder, I. E.，Putz, T.，Horninger, W. 等，Interleukin-6regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.Cancer Res 1998, 58, 4640-4645.
[0241][1引Nakashima, J.，Tachibana, M.，Horiguchi, Y.，Oya, M.等，Serum interleukin 6as a prognostic factor in patients with prostate cancer.Clin Cancer Res 2000, 6, 2702-2706.
[024引 [19]Ma化aroo-Ball, B.，Ball, G.，Rees, R.，Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches-a prostate cancer perspective. Vaccine 2007,25Suppl 2,BllO-121.
[0243][20]McLerran, D.，Grizzle,W.E.，Feng,Z.，Thompson, I. M.等，沈LDI-TOF MS whole serum proteomic profiling with I MAC surface does not reliably detect prostate cancer. Clin Qiem 2008,54,53-60.
[0244][21]Goo, Y. A.，Goodlett, D.民.，Advances in proteomic prostate cancer biomarker discovery. J F*roteomics 2010,73,1839-1850.
[024引 [22]Hanash, S. , Disease proteomics. Na化re 2003, 422, 226-232.
[024引 [23]加，S.，Loo, J. A.，Wong, D. T.，Human body fluid proteome analysis. Rroteomics 2006,6,6326-6353.
[0247][24]民amachandran, N.，Srivastava, S.，Labaer, J.，Applications of protein microarrays for biomarker discovery. Proteomics Clin Appl 2008,2,1444-1459.
[0248][25]Haab,B. B.，Applications of antibody array platforms. Curr Opin Biotechnol 2006,17,415-421.
[0249][26]Borrebaeck, C. A.，Wingren, C.，Design of high-density antibody microarrays for disease proteomics:key technological issues.J Proteomics 2009, 72, 928-935.
[0250] [27] Borrebaeck, C. A.，Wingren, C.，民ecombinant antibodies for the generation of antibody arrays. Methods Mol Biol 2011,785,247-262.
[0251][28] Ingvarsson, J.，Larsson, A.，Sjoholm, A. G.，Truedsson, L.等，Design of recombinant antibody microarrays for serum protein profiling:targeting of complement proteins. J Proteome Res 2007,6,3527-3536.
[0252] [29]Wi打gre打，C.，I打gvarsso打，J.，Dexli打，L.，Szul, D.，Borrebaeck, C. A.，Desig打 of recombinant antibody microarrays for complex proteome analysis:choice of sample labeling-tag and solid support. Proteomics 2007,7,3055-3065.
[0253][30]Dexlin_Mellby, L.，Sandstrom, A.，Antberg, L.，Gunnarsson, J.等，Design of recombinant antibody microarrays for membrane protein profiling of cell lysates and tissue extracts. Proteomics 2011,11,1550-1554.
[0254][3 1]Kr i s t ensson,Μ·，01 ssonΚ·，Car 1 sonJ.，Wu 111Β·，Sturf e 11 G.，Borrebaeck CAK. and Wingren C.，Design of民ecombinant Antibody Microarrays for Urinary Proteomics. Proteomics-Clinical Applications 2012, In press.
[0255][32]Carlsso打，A.，Wi打gre打，C.，I打gvarsso打，J.，Ellmark, P.等，Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays. Eur J Cancer 2008,44,472-480.
[0256][33] Ingvarsson, J.，Wingren, C.，Carlsson, A.，Ellmark, P.等，Detection of pancreatic cancer using antibody microarray-based serum protein profiling. 化oteomics 2008,8,2211-2219.
[0巧7] [34]Dexlin-Mel；Lby，L.，Sandstrom, A.，Centlow, M.，Nygren, S.等，Tissue proteome profiling of preeclamptic placenta using recombinant antibody microarrays. Proteomics Clin Appl 2010,4,794-807.
[0258] [35] Carlsson, A.，Persson, 0·，Ingvarsson, J.，Widegren, B.等，Plasma proteome profiling reveals biomarker patterns associated with prognosis and therapy selection in glioblastoma multiforme patients. Proteomics Clin Appl 2010,4, 591-602.
[0巧9] [36]Carlsson, A.，Wuttge, D. M.，Ingvarsson, J.，Bengtsson, A. A.等，Serum protein profiling of systemic lupus erythematosus and systemic sclerosis using recombinant antibody microarrays. Mol Cell Proteomics 2011,10,1110005033.
[0260][37]Carlsson, A.，Wingren, C.，Kristensson, M.，民ose, C.等，Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases.F*roc Natl Acad Sci U S A 2011,108,14252-14257.
[0261][38]Lilj a, H.，Cronin, A. M.，Dahl in, A.，Man jer, J.等，Prediction of significant prostate cancer diagnosed 20to SOyears later with a single measure of prostate-specific antigen at or before age 50. Cancer 2011, 117, 1210-1219.
[0262] [39] Lil ja, H. , Ulmert, D. , Vickers, A. J. , Prostate-specific antigen and prostate cancer:prediction, detection and monitoring. Nat Rev Cancer 2008, 8, 268-278.
[0263][40] Thompson, I. M.，Pauler, D. K.，Goodman, P. J.，化打容目]!，C. M.等，Prevalence of prostate cancer among men with a prostate-specific antigen leveKor = 4. Ong per milliliter. N Engl J Med 2004,350,2239-2246.
[0264][41] Vickers, A. J.，Oonin, A. M.，Bjork, T.，Manjer, J.等，Prostate specific antigen concentration at age 60and death or metastasis from prostate cancer:case-control s化dy.BMJ 2010,341，c4521.
[0265][42] Soderlind, E.，Strandberg, L.，Jirholt, P.，Kobayashi, N.等，民ecombining germline-derived CD民sequences for creating diverse single-framework antibody libraries. Nat Biotechnol 2000,18,852-856.
[0266] [43] Ihaka民.，民.G.，民：A language for data analysis and graphics. J Computational and Graphicla Statistics 1996, 5, 299-314.
[0267] [44]Eisen, Μ· Β·，Spellman, Ρ· Τ·，Brown, Ρ· 0·，Botstein, D.，Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998,95, 14863-14868.
[0268] [45] Shafer, M. W.，Mangold, L.，Partin, A. W.，Haab, B. B.，Antibody array profiling reveals serum TSP-las a marker to distinguish benign from malignant prostatic disease. Prostate 2007,67,255-267.
[0269][46]Tan, E. M.，Zhang, J.，Autoantibodies to tumor-associated antigens:reporters from the immune system. Immunol Rev 2008,222,328-340.
[0270][47] Chaudhuri, D.，Suriano,民.，Mittelman, A.，Tiwari,民.K.，Targeting the immune system in cancer. Curr Pharm Biotechno1 2009, 10, 166-184.
[0271] [48] Chow, M. T.，Holier, A.，Smyth, M. J.，Inf 1 animation and immune surveillance in cancer. Semin Cancer Biol 2011.
[027引[49]Shariat, S. F.，Karam, J. A.，Margulis,V.，Karakiewicz, P. I.，New blood-based biomarkers for the diagnosis，staging and prognosis of prostate cancer. BJU Int 2008, 101,675-683.
[027引[50]Bastian, P. J.，Carter, B.比，Bjai'tell, A.，Seitz, M.等，Insignificant prostate cancer and active surveillance:from definition to clinical implications. Eur Urol 2009,55, 1321-1330.
[0274] [51]D' Amico, A.V.，Whittington, R.，Malkowicz, S. B.，Schultz, D. 等，Biochemical outcome after radical prostatectomy, external beam radiation therapy，or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280, 969-974.
[0275][52]民eis, S. T.，Pontes-Junior, J.，Antunes, A. A.，Sousa-Canavez, J. M.等，Tgf-betalexpressio打as a biomarker of poor prognosis in prostate cancer. Clinics (Sao Paulo)2011，66, 1143-1147.
[0276][53]Ricote, M.，Garcia-Tunon, I.，Bethencourt, F. R.，Fraile, B. 等，Interleukin-l (IL-lalpha and IL-lbeta) and its receptors (IL-l民I，IL-l民II，and 比-IRa) in prostate carcinoma. Cancer 2004,100,1388-1396.
[0277][54] van Golen, K. L.，Ying, C.，Sequeira, L.，Dubyk, C. W.等，CCL2induces prostate cancer transendothelial cell migration via activation of the small GTPase Rac.J Cell Biochem 2008, 104, 1587-1597.
[0278][55] Jorgensen, T.，Berner, A.，Kaalhus, 0.，Tveter, K. J.等，Up-regulation of the oligosaccharide sialyl LewisX:a new prognostic parameter in metastatic prostate cancer. Cancer民es 1995,55, 1817-1819.
[0279] 巧6] Hong, Q.，Sze, C. I